Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Taysha Gene Therapies, Inc.
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
June 22, 2026
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
April 30, 2026
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
April 29, 2026
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
1
2
Next Page
→